Navigation Links
Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
Date:10/29/2008

PALO ALTO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced top-line results from an interrupted Phase 3 randomized study of Telcyta (canfosfamide HCL) in combination with pegylated liposomal doxorubicin (PLD) versus PLD alone in second-line therapy in platinum refractory, primary platinum resistant or secondary platinum resistant ovarian cancer (definitions of platinum status are provided below).

On an intent-to-treat (ITT) basis for the 125 enrolled patients, the median progression-free survival (PFS) was 5.6 months on the Telcyta plus PLD arm compared to 3.7 months on the PLD control arm, p = 0.7243 and hazard ratio (HR) = 0.92. The study did not meet the statistical significance p less than or equal to 0.05. The overall response rate as measured by RECIST was 12%, including one complete response (CR) for the Telcyta plus PLD arm and 8% for the PLD control arm.

Of the 125 patients in the ITT population, a prespecified analysis was conducted for 75 patients with platinum refractory or primary platinum resistant disease, including 40 patients on the Telcyta plus PLD arm and 35 patients on the PLD control arm. The median PFS of these patients was 5.6 months for the Telcyta plus PLD arm compared to 2.9 months for the PLD control arm, p = 0.0425 and HR = 0.55. The response rate, as assessed by RECIST, was 15%, including one CR for the Telcyta plus PLD arm and 6% for the PLD control arm.

The initial trial design provided for the enrollment of 244 patients. The trial was interrupted by a brief clinical hold, followed by a partial clinical hold from June 2007 until October 2007. At the time of the clinical hold, 125 patients had been enrolled in the trial. Although enrollment was permitted after the release of the clinical hold, Telik decided not to enroll additional patients, a decision which impacted the powering of the study.

The 125 patients randomized to the trial were well-balanced for patient demographics and key ovarian cancer disease characteristics. Telcyta was administered at 1000 mg/m2 followed by PLD at 50 mg/m2, the approved dose of PLD, every 28 days. Thirty-five patients were not able to complete their assigned per-protocol therapy and discontinued due to the clinical hold, including 21 patients on the Telcyta plus PLD arm and 14 patients on the PLD control arm.

There was a higher incidence of hematologic adverse events (AEs) in patients on the Telcyta plus PLD arm (66%) versus 44% on the PLD arm. The hematologic toxicities were manageable with dose reductions and growth factor support on both treatment arms.

The most common, non-hematologic adverse events, including nausea, fatigue, vomiting, and constipation, were similar in incidence and severity on both arms. Seventeen percent Grade 2 and 3 stomatitis and 9% Grade 2 and 3 palmar-plantar erythrodysesthesia (PPE) were observed on the Telcyta plus PLD arm, compared to 23% Grade 2 and 3 stomatitis and 21% Grade 2 and 3 PPE on the PLD control arm. Grade 4 PPE (2%) was only observed on the PLD control arm. Telcyta may ameliorate the incidence and severity of stomatitis and PPE known to be associated with PLD.

The results will be presented at an upcoming scientific conference.

About Platinum Refractory and Resistant Ovarian Cancer

Platinum refractory or primary platinum-resistance is defined as those patients whose disease fails to respond or relapses within 6 months of completion of initial platinum-based treatment. Secondary platinum resistance is defined as those patients whose disease relapses after 6 months of completion of therapy and fails a reinduction platinum-based regimen.

About Telik

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com.

This press release contains "forward-looking" statements. These include statements concerning the potential for TELCYTA to treat ovarian cancer and the effectiveness of TELCYTA in combination with PLD and in patients under certain platinum refractory and platinum resistant conditions. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including the risks associated with clinical trials and the interpretation of resulting data. Detailed information regarding these and other factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended June 30, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
2. Telik Announces Receipt of Nasdaq Notice
3. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
4. ReceptorBio Announces Diabetes License Agreement With Telik
5. Telik Announces Financial Results For 2008 Second Quarter
6. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
7. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
8. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
9. Telik Announces First Quarter 2008 Financial Results
10. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
11. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... San Francisco, CA (PRWEB) , ... February 20, ... ... Inspirata®, Inc. announced today the re-launch of “Crosswalk Insight: Oncology™” (Crosswalk), a unique ... enhanced version of Crosswalk can now be accessed through Inspirata’s diagnostic cockpit and ...
(Date:2/20/2017)... 2017  At the 2017 Health Information Management ... , IBM (NYSE: IBM ) today ... Chairman, President and CEO Ginni Rometty ... from 8:30-10 am ET, broadcast live on ... remarks examine the advent of the Cognitive Era ...
(Date:2/18/2017)... ... February 17, 2017 , ... A leader ... Hong Kong. , Nerium International is proud to introduce its Age-Defying Night Cream, ... NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products contain innovative ...
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model ... world’s leading maker of unmanned aircraft systems (UAS), are launching a joint program ... drones effectively, and support educational outreach efforts. , AMA and DJI will collaborate ...
Breaking Biology Technology:
(Date:2/3/2017)... -- A new independent identity strategy consultancy firm announces ... Designed to fill a critical niche in technical and ... Mark Crego and Janice Kephart ... expertise that span federal governments, the 9/11 Commission, private ... expertise has a common theme born from a shared ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
Breaking Biology News(10 mins):